Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

HeartBeam, Inc. BEAT

Healthcare  —  Health Information Services
0.36 (0.02) (5.26%) as of 25 Sep
Market cap
$21.7M
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

HeartBeam, Inc. (BEAT) Business Profile

Updated before January 2025

Company Overview

HeartBeam, Inc. (NASDAQ: BEAT) is a cutting-edge medical technology company specializing in the development of innovative cardiac care solutions. Founded in 2015 and headquartered in Santa Clara, California, HeartBeam aims to revolutionize the way cardiovascular diseases are diagnosed and managed. The company was established by Dr. Branislav Vajdic, a seasoned entrepreneur and technologist with a strong background in healthcare innovation. Dr. Vajdic serves as the CEO and has been instrumental in driving the company’s vision of providing accessible and accurate cardiac diagnostics to patients worldwide. HeartBeam’s leadership team comprises experienced professionals from the medical, technology, and business sectors, ensuring a well-rounded approach to innovation and growth.

Core Business Segments

HeartBeam focuses on the development and commercialization of advanced cardiac diagnostic tools. Its primary product categories include:

1. Portable Cardiac Diagnostic Devices

HeartBeam’s flagship product is a portable, credit card-sized device designed to provide remote cardiac monitoring and diagnostics. This device enables patients to record their heart activity anytime and anywhere, offering a convenient solution for those at risk of cardiac events. The device integrates with a cloud-based platform to deliver real-time data to healthcare providers.

2. Cloud-Based Diagnostic Platform

The company’s cloud-based platform is a critical component of its product ecosystem. It processes and analyzes data collected from the portable device, providing healthcare professionals with actionable insights. The platform leverages advanced algorithms and artificial intelligence to enhance diagnostic accuracy and efficiency.

3. Software Solutions for Healthcare Providers

HeartBeam also offers software solutions tailored for hospitals, clinics, and telemedicine providers. These solutions facilitate seamless integration of HeartBeam’s diagnostic tools into existing healthcare workflows, improving patient outcomes and operational efficiency.

Business Model

HeartBeam operates on a hybrid business model that combines product sales, subscription-based services, and licensing agreements. The company generates revenue through the following channels:

  • Device Sales: HeartBeam sells its portable cardiac diagnostic devices directly to consumers and healthcare providers.
  • Subscription Services: The cloud-based diagnostic platform operates on a subscription model, providing recurring revenue streams.
  • Licensing Agreements: HeartBeam licenses its proprietary technology to third-party medical device manufacturers and healthcare organizations.

This diversified revenue model ensures financial stability and supports the company’s long-term growth objectives.

Strategic Direction

HeartBeam is committed to expanding its product portfolio and market presence. Key strategic initiatives include:

  • Product Innovation: The company is investing heavily in research and development to enhance its existing products and develop new solutions. Future product categories may include wearable cardiac monitors and advanced AI-driven diagnostic tools.
  • Global Expansion: HeartBeam aims to enter new geographic markets, particularly in regions with high prevalence of cardiovascular diseases.
  • Sustainability Goals: The company is focused on minimizing its environmental footprint by adopting sustainable manufacturing practices and reducing waste.
  • Partnerships and Collaborations: HeartBeam is actively seeking partnerships with healthcare providers, technology companies, and research institutions to accelerate innovation and market adoption.

Competitive Landscape

HeartBeam operates in a highly competitive market, facing competition from established medical device companies and emerging startups. Key competitors include:

  • AliveCor: Known for its KardiaMobile ECG devices, AliveCor is a major player in the portable cardiac monitoring space.
  • iRhythm Technologies: Specializes in wearable cardiac monitors and diagnostic services.
  • Medtronic: A global leader in medical technology, offering a wide range of cardiac care solutions.
  • BioTelemetry (a Philips company): Provides remote cardiac monitoring and diagnostic services.

Despite the competition, HeartBeam differentiates itself through its innovative product design, user-friendly technology, and focus on accessibility.

Risk Factors

HeartBeam faces several risks that could impact its business operations and financial performance:

  • Market Dependence: The company’s success is heavily reliant on the adoption of its products and services by healthcare providers and patients.
  • Regulatory Challenges: As a medical device company, HeartBeam must navigate complex regulatory environments, which can delay product approvals and market entry.
  • Supply Chain Disruptions: Dependence on third-party suppliers for components and manufacturing poses a risk of supply chain disruptions.
  • Competition: Intense competition from established players and new entrants could impact market share and pricing power.

Recent Developments

HeartBeam has made significant strides in recent months, including:

  • FDA Clearance: The company received FDA clearance for its portable cardiac diagnostic device, paving the way for commercialization in the U.S. market.
  • Strategic Partnerships: HeartBeam announced collaborations with leading healthcare providers to pilot its diagnostic solutions.
  • Product Enhancements: The company introduced new features to its cloud-based platform, including enhanced AI algorithms for improved diagnostic accuracy.
  • Global Developments: The COVID-19 pandemic highlighted the importance of remote healthcare solutions, driving increased demand for HeartBeam’s products.

Investment Considerations

Strengths

  • Innovative Technology: HeartBeam’s cutting-edge products and AI-driven platform set it apart from competitors.
  • Growing Market: The global cardiac diagnostics market is expanding, providing significant growth opportunities.
  • Experienced Leadership: The company’s leadership team brings a wealth of expertise in healthcare and technology.

Risks

  • Regulatory Hurdles: Delays in regulatory approvals could impact product launches and revenue growth.
  • Market Competition: Intense competition may limit market penetration and profitability.
  • Financial Stability: As a relatively young company, HeartBeam may face challenges in achieving consistent profitability.

Conclusion

HeartBeam, Inc. is well-positioned to become a leader in the cardiac diagnostics market. With its innovative products, robust business model, and strategic growth initiatives, the company has a strong foundation for future success. However, investors should carefully consider the associated risks before making investment decisions. As the demand for remote healthcare solutions continues to grow, HeartBeam is poised to play a pivotal role in shaping the future of cardiac care.